A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

Abstract Background Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. One of the major goals in this palliative setting is to develop chemoth...

Full description

Bibliographic Details
Main Authors: Alexander Grunenberg, Lisa M. Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Möller, Thomas F. E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter, Christian Buske
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Subjects:
Marginal zone lymphoma
PI3K inhibitor
Copanlisib
Rituximab
Online Access:https://doi.org/10.1186/s12885-021-08464-6

Internet

https://doi.org/10.1186/s12885-021-08464-6

Similar Items